Last reviewed · How we verify
NCT05295667
Doppler and AFV for Outcome Prediction ın FGR
trial testing Doppler measurement in combination with amniotic fluid volume in Fetal Growth Retardation in 100 participants. Completed in 30 June 2020.
1 June 2020
Quick facts
| Lead sponsor | Istanbul Bakirkoy Maternity and Children Diseases Hospital |
|---|---|
| Status | Completed |
| Study type | OBSERVATIONAL |
| Enrollment | 100 |
| Start date | 1 June 2020 |
| Primary completion | 1 June 2020 |
| Estimated completion | 30 June 2020 |
| Sites | 1 location across Turkey (Türkiye) |
Drugs / interventions tested
- Doppler measurement in combination with amniotic fluid volume
Conditions studied
- Fetal Growth Retardation — all drugs for Fetal Growth Retardation →
Sponsor
Istanbul Bakirkoy Maternity and Children Diseases Hospital
Who can join
Adults 18 to 40, female only, with Fetal Growth Retardation. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The investigator contrived a prospective study of AUCR to compare its association to adverse perinatal outcomes with other established doppler parameters, such as CPR and UCR within a population of suspected FGR fetuses at term.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT05295667
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Fetal Growth Retardation
Currently open trials in the same condition.
- NCT06952777 — Validation of Sensors for Long-term Non-Invasive Fetal Monitoring · NA · recruiting
- NCT06405360 — DEUX OEUFs: Cracking the Potential of Eggs to Improve Child Growth and Development · NA · active not recruiting
- NCT06096805 — Prediction of Placental Fetal Growth Restriction in High Risk Population (PoPFGR) · recruiting
- NCT06215690 — Evaluation of Anterior Middle Brain Structures With Cerebrovascular Flow in Fetuses With Fetal Growth Restriction · active not recruiting
- NCT06416995 — Serum Vasohibin, Cardiotrophin, Endocan & Perinatal Outcomes · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05295667 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Istanbul Bakirkoy Maternity and Children Diseases Hospital
- Last refreshed: 25 March 2022
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05295667.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing